Low but Increasing Prevalence of Reduced Beta-lactam Susceptibility Among Invasive Group B Streptococcal Isolates, US Population-Based Surveillance, 1998-2018.
group B Streptococcus
penicillin binding protein 2x
reduced beta-lactam susceptibility
whole-genome sequencing
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
29
10
2020
accepted:
16
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
Invasive group B We analyzed iGBS isolates from 8 multistate population-based surveillance sites from 1998 to 2018. During 1998-2014, phenotypic antimicrobial susceptibility was determined by broth microdilution; criteria for 6 antibiotics were used to identify RBLS, followed by whole-genome sequencing (WGS). WGS for all isolates was added in 2015; we used phenotypic and genotypic results of >2000 isolates to validate phenotypic RBLS criteria and genotypic predictions. Since 2016, WGS has been used to screen for RBLS with broth microdilution confirmation of predicted RBLS isolates. Of 28 269 iGBS isolates, 28 (0.1%) were nonsusceptible by CLSI criteria; 137 (0.5%) met RBLS criteria. RBLS isolates were detected in all Active Bacterial Core surveillance sites. The RBLS proportion increased, especially since 2013 (odds ratio, 1.17; 95% CI, 1.03-1.32); the proportion that were nonsusceptible remained stable. The RBSL proportion was low but increasing among US iGBS isolates. Ongoing monitoring is needed to detect emerging threats to prevention and treatment of GBS infections.
Sections du résumé
BACKGROUND
BACKGROUND
Invasive group B
METHODS
METHODS
We analyzed iGBS isolates from 8 multistate population-based surveillance sites from 1998 to 2018. During 1998-2014, phenotypic antimicrobial susceptibility was determined by broth microdilution; criteria for 6 antibiotics were used to identify RBLS, followed by whole-genome sequencing (WGS). WGS for all isolates was added in 2015; we used phenotypic and genotypic results of >2000 isolates to validate phenotypic RBLS criteria and genotypic predictions. Since 2016, WGS has been used to screen for RBLS with broth microdilution confirmation of predicted RBLS isolates.
RESULTS
RESULTS
Of 28 269 iGBS isolates, 28 (0.1%) were nonsusceptible by CLSI criteria; 137 (0.5%) met RBLS criteria. RBLS isolates were detected in all Active Bacterial Core surveillance sites. The RBLS proportion increased, especially since 2013 (odds ratio, 1.17; 95% CI, 1.03-1.32); the proportion that were nonsusceptible remained stable.
CONCLUSIONS
CONCLUSIONS
The RBSL proportion was low but increasing among US iGBS isolates. Ongoing monitoring is needed to detect emerging threats to prevention and treatment of GBS infections.
Identifiants
pubmed: 33553474
doi: 10.1093/ofid/ofaa634
pii: ofaa634
pmc: PMC7850125
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa634Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
Références
Clin Infect Dis. 2021 Mar 15;72(6):1004-1013
pubmed: 32060499
Antimicrob Agents Chemother. 2008 Aug;52(8):2890-7
pubmed: 18490507
JAMA Intern Med. 2019 Apr 1;179(4):479-488
pubmed: 30776079
J Infect Dis. 2001 Jul 1;184(1):66-72
pubmed: 11398111
Antimicrob Agents Chemother. 2008 Aug;52(8):2915-8
pubmed: 18541727
J Clin Microbiol. 2003 Sep;41(9):4445-7
pubmed: 12958289
J Microbiol Methods. 2010 Feb;80(2):212-4
pubmed: 19958797
Circulation. 2015 Oct 13;132(15):1435-86
pubmed: 26373316
JAMA Pediatr. 2019 Mar 1;173(3):224-233
pubmed: 30640366
Clin Microbiol Infect. 2017 Aug;23(8):574.e7-574.e14
pubmed: 28257899
Obstet Gynecol. 2019 Jul;134(1):1
pubmed: 31241599
J Clin Microbiol. 2014 Sep;52(9):3406-10
pubmed: 24920773
J Infect Dis. 2006 May 1;193(9):1296-303
pubmed: 16586368
Mol Microbiol. 2012 Nov;86(3):692-706
pubmed: 22931193
Clin Infect Dis. 2012 Jun;54(12):1679-84
pubmed: 22619239
Emerg Infect Dis. 2015 Sep;21(9):1520-8
pubmed: 26292067
J Clin Microbiol. 1990 Jan;28(1):5-7
pubmed: 2405014
Clin Infect Dis. 2020 Jun 24;71(1):201-204
pubmed: 31630171